TY - JOUR
T1 - Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction Insights from the EXAMINATION trial
AU - Brugaletta, S
AU - Sabate, M
AU - Martin-Yuste, V
AU - Masotti, M
AU - Shiratori, Y
AU - Alvarez-Contreras, L
AU - Cequier, A
AU - Iniguez, A
AU - Serra, A
AU - Hernandez-Antolin, R
AU - Mainar, V
AU - Valgimigli, M (Marco)
AU - Tespili, M
AU - den Heijer, P
AU - Bethencourt, A
AU - Vazquez, N
AU - Gomez Lara, Josep
AU - Backx, B
AU - Serruys, PWJC (Patrick)
PY - 2013
Y1 - 2013
N2 - Background: Few data are available about safety of second generation drug eluting stents in an all-comer ST elevation myocardial infarction (STEMI) population. We sought to investigate the predictors and clinical implications of 1-year stent thrombosis (ST) in patients with STEMI, included in the EXAMINATION trial. Methods and results: The EXAMINATION trial is an all-comer prospective, randomized 1: 1 controlled trial, testing everolimus-eluting stent (EES) vs. cobalt chromium bare metal stent (BMS) in STEMI patients. It included 1498 patients, randomized to EES (n = 751) or BMS (n = 747). At 1 year, definite/probable stent thrombosis, defined according to ARC criteria, occurred in 26 patients (1.73%), including 18 definite and 8 probable events. The incidence of ST was lower in patients treated with EES t Conclusions: ST had low frequency in the first year after implantation of EES/BMS in STEMI patients, but it is associated with adverse events. BMS implantation, lack of ST-segment resolution and high Killip class on admission were independent predictors of 1-year ST. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
AB - Background: Few data are available about safety of second generation drug eluting stents in an all-comer ST elevation myocardial infarction (STEMI) population. We sought to investigate the predictors and clinical implications of 1-year stent thrombosis (ST) in patients with STEMI, included in the EXAMINATION trial. Methods and results: The EXAMINATION trial is an all-comer prospective, randomized 1: 1 controlled trial, testing everolimus-eluting stent (EES) vs. cobalt chromium bare metal stent (BMS) in STEMI patients. It included 1498 patients, randomized to EES (n = 751) or BMS (n = 747). At 1 year, definite/probable stent thrombosis, defined according to ARC criteria, occurred in 26 patients (1.73%), including 18 definite and 8 probable events. The incidence of ST was lower in patients treated with EES t Conclusions: ST had low frequency in the first year after implantation of EES/BMS in STEMI patients, but it is associated with adverse events. BMS implantation, lack of ST-segment resolution and high Killip class on admission were independent predictors of 1-year ST. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
U2 - 10.1016/j.ijcard.2013.03.036
DO - 10.1016/j.ijcard.2013.03.036
M3 - Article
C2 - 23578890
SN - 0167-5273
VL - 168
SP - 2632
EP - 2636
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 3
ER -